|
1.
|
Wagner M, Redaelli C, Lietz M, Seiler CA,
Friess H and Buchler MW: Curative resection is the single most
important factor determining outcome in patients with pancreatic
adenocarcinoma. Br J Surg. 91:586–594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bramhall SR, Allum WH, Jones AG, Allwood
A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560
patients with pancreatic cancer, and incidence of the disease, in
the West Midlands: an epidemiological study. Br J Surg. 82:111–115.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
4.
|
McCracken M, Olsen M, Chen MS Jr, et al:
Cancer incidence, mortality, and associated risk factors among
Asian Americans of Chinese, Filipino, Vietnamese, Korean, and
Japanese ethnicities. CA Cancer J Clin. 57:190–205. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Buchler MW, Wagner M, Schmied BM, Uhl W,
Friess H and Z’Graggen K: Changes in morbidity after pancreatic
resection: toward the end of completion pancreatectomy. Arch Surg.
138:1310–1315. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Diener MK, Heukaufer C, Schwarzer G, et
al: Pancreaticoduodenectomy (classic Whipple) versus
pylorus-preserving pancreaticoduodenectomy (pp Whipple) for
surgical treatment of periampullary and pancreatic carcinoma.
Cochrane Database Syst Re. 16:CD0060532008.
|
|
7.
|
Jaffee EM, Hruban RH, Biedrzycki B, et al:
Novel allogeneic granulocyte-macrophage colony-stimulating
factor-secreting tumor vaccine for pancreatic cancer: a phase I
trial of safety and immune activation. J Clin Oncol. 19:145–156.
2001.
|
|
8.
|
Picozzi VJ, Kozarek RA and Traverso LW:
Interferon-based adjuvant chemoradiation therapy after
pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg.
185:476–480. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Dranoff G: Coordinated tumor immunity. J
Clin Invest. 111:1116–1118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Groh V, Rhinehart R, Secrist H, Bauer S,
Grabstein KH and Spies T: Broad tumor-associated expression and
recognition by tumor-derived gamma delta T cells of MICA and MICB.
Proc Natl Acad Sci USA. 96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Pende D, Rivera P, Marcenaro S, et al:
Major histocompatibility complex class I-related chain A and
UL16-binding protein expression on tumor cell lines of different
histotypes: analysis of tumor susceptibility to NKG2D-dependent
natural killer cell cytotoxicity. Cancer Res. 62:6178–6186.
2002.
|
|
13.
|
Liu G, Atteridge CL, Wang X, Lundgren AD
and Wu JD: The membrane type matrix metalloproteinase MMP14
mediates constitutive shedding of MHC class I chain-related
molecule A independent of A disintegrin and metalloproteinases. J
Immunol. 184:3346–3350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Salih HR, Rammensee HG and Steinle A:
Cutting edge: down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Waldhauer I, Goehlsdorf D, Gieseke F, et
al: Tumor-associated MICA is shed by ADAM proteases. Cancer Res.
68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Doubrovina ES, Doubrovin MM, Vider E, et
al: Evasion from NK cell immunity by MHC class I chain-related
molecules expressing colon adenocarcinoma. J Immunol.
171:6891–6899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Xu X, Rao G, Gaffud MJ, et al:
Clinicopathological significance of major histocompatibility
complex class I-related chain a and B expression in thyroid cancer.
J Clin Endocrinol Metab. 91:2704–2712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Xu X, Rao GS, Groh V, et al: Major
histocompatibility complex class I-related chain A/B (MICA/B)
expression in tumor tissue and serum of pancreatic cancer: role of
uric acid accumulation in gemcitabine-induced MICA/B expression.
BMC Cancer. 11:1942011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Duan X, Deng L, Chen X, et al: Clinical
significance of the immunostimulatory MHC class I chain-related
molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med
Oncol. 28:466–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Groh V, Bahram S, Bauer S, Herman A,
Beauchamp M and Spies T: Cell stress-regulated human major
histocompatibility complex class I gene expressed in
gastrointestinal epithelium. Proc Natl Acad Sci USA.
93:12445–12450. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Bauer S, Groh V, Wu J, et al: Activation
of NK cells and T cells by NKG2D, a receptor for stress-inducible
MICA. Science. 285:727–729. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Diefenbach A, Jensen ER, Jamieson AM and
Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate
tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hayakawa Y, Kelly JM, Westwood JA, et al:
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand
interaction is dependent upon perforin. J Immunol. 169:5377–5381.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Raulet DH: Roles of the NKG2D
immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Watson NF, Spendlove I, Madjd Z, et al:
Expression of the stress-related MHC class I chain-related protein
MICA is an indicator of good prognosis in colorectal cancer
patients. Int J Cancer. 118:1445–1452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Marten A, von Lilienfeld-Toal M, Buchler
MW and Schmidt J: Soluble MIC is elevated in the serum of patients
with pancreatic carcinoma diminishing gammadelta T cell
cytotoxicity. Int J Cancer. 119:2359–2365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Holdenrieder S, Stieber P, Peterfi A,
Nagel D, Steinle A and Salih HR: Soluble MICA in malignant
diseases. Int J Cancer. 118:684–687. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Chung HW and Lim JB: Clinical significance
of serum levels of immune-associated molecules, uric acid and
soluble MHC class I chain-related molecules A and B, as diagnostic
tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci.
102:1673–1679. 2011. View Article : Google Scholar
|
|
29.
|
Bahram S: MIC genes: from genetics to
biology. Adv Immunol. 76:1–60. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Collins RW, Stephens HA, Clare MA and
Vaughan RW: High resolution molecular phototyping of MICA and MICB
alleles using sequence specific primers. Hum Immunol. 63:783–794.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Stephens HA: MICA and MICB genes: can the
enigma of their polymorphism be resolved? Trends Immunol.
22:378–385. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Arreygue-Garcia NA, Daneri-Navarro A, del
Toro-Arreola A, et al: Augmented serum level of major
histocompatibility complex class I-related chain A (MICA) protein
and reduced NKG2D expression on NK and T cells in patients with
cervical cancer and precursor lesions. BMC Cancer. 8:162008.
View Article : Google Scholar
|
|
33.
|
Chitadze G, Lettau M, Bhat J, et al:
Shedding of endogenous MHC class I-related chain molecules A and B
from different human tumor entities: heterogeneous involvement of
the ‘a disintegrin and metalloproteases’ 10 and 17. Int J Cancer.
133:1557–1566. 2013.PubMed/NCBI
|
|
34.
|
Ashiru O, Boutet P, Fernandez-Messina L,
et al: Natural killer cell cytotoxicity is suppressed by exposure
to the human NKG2D ligand MICA*008 that is shed by tumor
cells in exosomes. Cancer Res. 70:481–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Collins RW: Human MHC class I chain
related (MIC) genes: their biological function and relevance to
disease and transplantation. Eur J Immunogenet. 31:105–114. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Bedel R, Thiery-Vuillemin A, Grandclement
C, et al: Novel role for STAT3 in transcriptional regulation of NK
immune cell targeting receptor MICA on cancer cells. Cancer Res.
71:1615–1626. 2011. View Article : Google Scholar : PubMed/NCBI
|
